Interviews

Because brentuximab vedotin is so effective in the relapsed and refractory setting, there has been a lot of excitement around assessing the treatment earlier in Hodgkin lymphoma, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.

While the community has seen the first clinical trials and first FDA-approved therapy for pediatric multiple sclerosis, it remains challenging to treat, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.

I think we’re in a bit of a lull for exciting new therapy developments, likely because the development of the checkpoint inhibitors has just been so extraordinary revolutionary, explained Janice Mehnert, MD, Head of the Phase I Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, and the Head of the Melanoma Research Team.

While it is likely that the Trump administration's proposed International Pricing Index would lower drug prices in the United States by at least a little, there are a number of potential unintended consequences that aren't clear at this point, said Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy; director of the Healthcare Markets and Regulation Lab in the Department of Health Care Policy at Harvard Medical School; and co-editor-in-chief of The American Journal of Managed Care®.

Community health workers act as translators, have immense understanding of the makeup of the community and its needs, and are in-tune to feelings around certain healthcare and nonhealthcare-related topics, explained Victor Murray, director for care management initiatives at the Camden Coalition of Healthcare Providers.

There are so many different areas that a social worker can help with in a medical practice that they can be more a case manager, pointing patients to resources for financial assistance, looking at their insurance, or helping with disability, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

The National Center for Complex Health and Social Needs sits at the intersection between healthcare and behavioral health and social services, and it is critically important that the systems work together to be able to serve the populations that we need them to serve, said Mavis Asiedu-Frimpong, director for national initiatives at the Camden Coalition of Healthcare Providers.

Currently, minimal residual disease testing is being used for prognostication not for treatment decisions, explained Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.

There are individuals who have a lot of needs and struggle to navigate different systems to get their needs met, and there are systems that don’t necessarily cooperate, partner, and collaborate in effective ways in order to address the needs of that cohort, said Victor Murray, director for care management initiatives at the Camden Coalition of Healthcare Providers.

Jeff Sharman, MD, medical oncologist, Willamette Valley Cancer Institute and Research Center; medical director, The US Oncology Network, explains how personalized medicine has changed the way physicians think about treatment for patients with chronic lymphocytic leukemia (CLL).

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo